AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Scheduled to Post Quarterly Earnings on Wednesday
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is scheduled to be announcing its earnings results after the market closes on Wednesday, July 26th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.06. The firm had revenue of $3.11 million during the quarter, compared to analysts’ expectations of $2.36 million. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 273.65%. On average, analysts expect AcelRx Pharmaceuticals to post $-1.15 EPS for the current fiscal year and $-0.86 EPS for the next fiscal year.
AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) opened at 3.10 on Wednesday. The stock’s market capitalization is $140.68 million. The stock has a 50 day moving average of $2.35 and a 200 day moving average of $2.71. AcelRx Pharmaceuticals, Inc. has a 52-week low of $1.95 and a 52-week high of $4.08.
COPYRIGHT VIOLATION WARNING: “AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Scheduled to Post Quarterly Earnings on Wednesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/19/acelrx-pharmaceuticals-inc-nasdaqacrx-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Several analysts have commented on the stock. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Wednesday, May 3rd. Jefferies Group LLC restated a “buy” rating and set a $7.00 target price on shares of AcelRx Pharmaceuticals in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $8.67.
In other news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the firm’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 28.10% of the stock is owned by company insiders.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.